| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression.
|
J Pharmacol Exp Ther
|
2009
|
1.09
|
|
2
|
Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.
|
J Neurosci
|
2002
|
0.97
|
|
3
|
Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
|
Exp Eye Res
|
2011
|
0.95
|
|
4
|
Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties.
|
Proc Natl Acad Sci U S A
|
2004
|
0.94
|
|
5
|
Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in parkinsonian mice via PI3K-Wnt/β-catenin dysregulation.
|
J Neurosci
|
2013
|
0.93
|
|
6
|
A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
|
J Ocul Pharmacol Ther
|
2010
|
0.91
|
|
7
|
Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
|
J Neuroinflammation
|
2010
|
0.89
|
|
8
|
Imidazenil: a low efficacy agonist at alpha1- but high efficacy at alpha5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem.
|
Neuropharmacology
|
2008
|
0.87
|
|
9
|
NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties.
|
Eur J Pharmacol
|
2007
|
0.86
|
|
10
|
NCX 2057, a novel NO-releasing derivative of ferulic acid, suppresses inflammatory and nociceptive responses in in vitro and in vivo models.
|
Br J Pharmacol
|
2009
|
0.86
|
|
11
|
Modulation of iNOS expression by a nitric oxide-releasing derivative of the natural antioxidant ferulic acid in activated RAW 264.7 macrophages.
|
Eur J Pharmacol
|
2006
|
0.85
|
|
12
|
A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury.
|
Br J Pharmacol
|
2003
|
0.84
|
|
13
|
A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology.
|
J Enzyme Inhib Med Chem
|
2011
|
0.81
|
|
14
|
Switching the microglial harmful phenotype promotes lifelong restoration of subtantia nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice.
|
Rejuvenation Res
|
2011
|
0.79
|
|
15
|
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma.
|
Bioorg Med Chem Lett
|
2009
|
0.78
|
|
16
|
Enhanced oxygen saturation in optic nerve head of non-human primate eyes following the intravitreal injection of NCX 434, an innovative nitric oxide-donating glucocorticoid.
|
J Ocul Pharmacol Ther
|
2011
|
0.76
|